1. A case of skin rash during oral administration of a novel androgen receptor inhibitor, darolutamide.
- Author
-
Shima, K., Nomura, T., Yamada, Y., Kobayashi, T., and Kabashima, K.
- Subjects
ANDROGEN receptors ,EXANTHEMA ,TOXIC epidermal necrolysis ,CASTRATION-resistant prostate cancer ,DRUG eruptions ,DRUG side effects ,PROSTATE cancer patients - Abstract
The incidence of rash caused by darolutamide in the ARAMIS trial was very low (2.9%).9 The rash types included combined dermatitis, erythema, rash, macular rash, maculopapular rash, papular rash and pustular rash, although the details of these cases have not been published. Several second-generation novel selective inhibitors of androgen receptor (AR), including apalutamide and darolutamide, are used to treat prostate cancers (PC).1 Some cases of apalutamide-caused drug eruption have been reported.2 However, cases of darolutamide-induced drug eruption have never been reported. The longer interval of darolutamide- and apalutamide-induced rash, as well as the negative LTT and absence of skin rash on the recommencement of darolutamide, suggest the presence of an unknown mechanism of drug eruption that is different from the canonical T-cell-mediated allergic reaction. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF